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Editorial on the Research Topic
Self-Eating on Demand: Autophagy in Cancer and Cancer Therapy
The field of autophagy has grown enormously over the past 10–15 years, with rapid advances in 
our understanding of the regulatory mechanisms that control autophagy pathways in mammalian 
systems, and an improved understanding of the physiological influences of autophagy in health 
and disease. Supporting such progress, there has been substantial diversification in assessment and 
modulation tools (1), assisted by the advancement of model reporter systems. Indeed, we are now 
starting to realize the potential for autophagy control for novel practical applications, including 
disease intervention and biotechnology. With the aim of promoting, supporting, and streamlining 
cooperative European research networks to realize the enormous potential of autophagy in the clinic 
and in industry, a collaborative consortium—called TransAutophagy—was approved in November 
2015 in the framework of the Horizon 2020 Program as a European Union CO-operation in Science 
and Technology (COST) Action (CA151381) (2). Sponsored for 4 years, this network includes more 
than 250 scientists from 21 countries, with each participant actively engaged in basic and/or trans-
lational autophagy research.
TransAutophagy comprises five different thematic Working Groups with activities designed to 
synergize and support translation of our ever-advancing basic autophagy knowledge into biomedical 
and biotechnological applications (2). Targeting the complex physiological and metabolic changes 
inherent within cancer cells during transformation, tumor growth, and metastasis, through manipu-
lation of autophagy regulatory networks, is a key objective because emerging evidence indicates that 
autophagy capability underpins a cancer cell’s ability to face the increasingly hostile tumor micro-
environment. Here, poor nutrient availability and elevated cellular stress place demands upon the 
cancer cell for an increased capability to adapt and survive. Several lines of evidence have established 
that cancer cells use autophagy as a highly plastic and dynamic mechanism to either repress initial 
steps in carcinogenesis or to support the survival and growth of established tumors (3). Moreover, it 
is becoming increasingly clear that autophagy regulates the intersection between cancer and stromal 
cells in tumors. The tumor-suppressing role of autophagy involves, e.g., (i) maintenance of genetic/
1 http://cost-transautophagy.eu.
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genomic stability; (ii) preservation of bioenergetics; (iii) reduction 
and control of (mutagenic/damaging) reactive oxygen species; 
(iv) degradation of oncogenic proteins; (v) activation of tumor-
suppressing mechanisms like oncogene-induced senescence and 
autophagic cell death; (vi) reduction of chronic inflammation; and 
(vii) regulation of immunosurveillance mechanisms [reviewed in 
Ref. (3, 4)]. This collection of reviews—comprising this research 
topic—addresses emerging traits highlighting how autophagy 
shapes the cancer cell-tumor microenvironment crosstalk.
The review of Mathiassen et  al. (Cecconi’s lab) discusses 
mounting evidence for new regulatory intersections between 
autophagy and the cell cycle, which need to be urgently validated 
in  vivo. At the mechanistic level, the tumor suppressor role of 
autophagy has been ascribed to its vital cell-autonomous func-
tions in mitigating damage and maintaining cellular integrity 
during metabolic stress. An emerging and intriguing link, which 
is discussed in the review of Kania et al. (Bultynck’s/Parys’s labs), 
is the regulation of autophagy in cancer cells through Ca2+ transfer 
from the ER to mitochondria via the inositol 1,4,5-trisphosphate 
receptor (IP3R) at ER–mitochondria contact sites. In a develop-
ing research area with enormous potential, the impact of miRNA-
mediated autophagy regulation on the tumor microenvironment 
and cancer growth, and their potential as cancer biomarkers and 
therapeutic targets, is discussed in the review of Gozuacik et al. 
(Gozuacik’s lab).
In established tumors, elevated levels of autophagy are often 
associated with poorly oxygenated regions where the demand for 
nutrients and the need to withstand diverse metabolic stresses 
are increased. As further discussed in the review of Viry et  al. 
(Janji’s lab), cancer cell-associated autophagy in hypoxic tumors 
plays a crucial role in modulating immunosurveillance and in 
fostering the immunosuppressive tumor microenvironment, by 
suppressing key mechanisms of innate and adaptive antitumor 
immunity, thus favoring tumor outgrow and dissemination. 
Consistent with this pro-tumorigenic role, advanced tumors often 
display an “autophagy-lysosomal addiction,” which appears to be 
required to maintain their energy balance through the recycling 
of intracellular components into biosynthetic pathways or ATP 
synthesis and to regulate secretion of pro-tumorigenic factors. 
In the review of New et al. (Tooze’s lab), the idea that advanced 
and aggressive mutant KRAS-driven tumors (such as pancreatic 
ductal adenocarcinomas) exploit a heightened autophagy– 
lysosomal pathway under the transcriptional control of the 
MiF/TFE factors to support energy metabolism and to allow 
growth under conditions of energy deficit and metabolic stress 
is discussed (5). Furthermore, the review of Iovanna (Iovanna’s 
lab) highlights the key role played by the pancreatitis-associated 
vacuolar protein 1 (VMP1) in pancreatic acinar cells and how its 
elevated expression drives early autophagy and cooperates with 
the KRAS oncogene to promote carcinogenesis in the pancreas.
Another emerging aspect linking autophagy to tumor pro-
gression, discussed in the review of Keulers et  al. (Rouschop’s 
lab), is the ability of advanced cancer cells to use autophagy as 
a trafficking and export mechanism of pro-tumorigenic factors, 
such as pro-inflammatory/pro-angiogenic cytokines or chemot-
actic/pro-invasive molecules. This cancer cell-autonomous trait 
further illustrates the plasticity of tumor-associated autophagy, 
which can enable and modulate the crosstalk between cancer and 
stromal cells thereby affecting the tumor microenvironment, a 
property that needs to be taken into consideration when consid-
ering therapeutic approaches. Based on the growing relevance of 
tumor-associated autophagy, many labs are developing and test-
ing the effects of autophagy modulators in cancer therapy. The 
recognition of the prevalent—albeit not unique—cytoprotective 
and stress adaptation roles of autophagy in advanced cancers has 
led to the assumption—as supported by in vitro and preclinical 
data—that blocking cancer cell-intrinsic autophagy may curtail 
cancer cell resistance to chemotherapy, thereby improving 
therapy outcome. Thus, the first-generation autophagy blockers, 
e.g., chloroquine and its derivative hydroxychloroquine (6, 7) 
are currently being tested in different clinical trials to potentiate 
patients’ responses to a variety of anticancer regimens.2 On the 
other hand, as autophagy can control both cell death and survival 
programs, the induction of autophagic cancer cell death elicited 
by certain anticancer therapies, may offer a therapeutically 
attractive strategy, especially when cancer cells display resistance 
to apoptosis, as discussed in the review by Fulda (Fulda’s lab). 
Finally, although autophagy is a highly dynamic process, the 
expression of certain autophagy genes in aggressive tumors like 
melanoma, may provide novel independent prognostic biomark-
ers for early stage neoplasms, as discussed in the review of Tang 
et al. (Lovat’s lab). This may help to identify patients at risk of 
disease progression, thus facilitating earlier patient therapeutic 
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